Accretive Health, the beleaguered Chicago-based revenue-cycle management firm, has set a firm date for reporting its long-delayed financial results for 2013.
The delay in filing its annual report for that year caused the company to be delisted from the New York Stock Exchange. It now trades on the over-the-counter market.
Accretive will report the results after the market closes on Dec. 30. The form 10-K will also include restated results for fiscal 2012 and 2011, which Accretive had been correcting to account for errors involving when it recognized revenue from its contracts.
Accretive last month said it planned to release the results in mid-December, but Monday's announcement marks the first time it has set a firm date.
Without the results, investors have had little information on the extent to which Accretive's recent operational and legal challenges have affected its top and bottom line. Those challenges include being banned from doing business in Minnesota for a period of time to settle allegations of overly aggressive bill collection practices and patient privacy violations; a settlement with the Federal Trade Commission over a 2011 data breach; a corporate restructuring; and a management shake-up.
Accretive shares had gained 1.75% on Monday morning to trade at $8.70.
Follow Beth Kutscher on Twitter: @MHbkutscher
